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The last two years have seen much excitement in the field of genetics with the identification of a formerly unappreciated level of "structural variation" within the normal human genome. Genetic structural variants include deletions, duplications and inversions in addition to the recently discovered, copy number variants (CNVs). Single nucleotide polymorphisms (SNPs) are the most extensively evaluated variant within the genome to date. Combining our knowledge from these studies with our rapidly accumulating understanding of structural variants, it is apparent that the extent of genetic dissimilarity between any two individuals is considerable and much greater than that which was previously recognized. Clearly, this more diverse view of the genome has significant implications for allogeneic hematopoietic stem cell transplantation (HSCT), not least in the generation of transplant antigens but also in terms of individual susceptibility to transplant related toxicities. With advances in DNA sequencing technology we now have the capacity to perform genome-wide analysis in a high throughput fashion, permitting a detailed genetic analysis of patient and donor prior to transplantation. Understanding the significance of this additional genetic information and applying it in a clinically meaningful way will be one of the challenges faced by transplant clinicians in the future.
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Structural Variation in the Human Genome
There has been much focus recently on documenting the extent of normal human genomic variation, particularly in the form of SNPs (see Table 1 ). In October 2005, Phase 1 of the International Hapmap Project was published 1 . This project catalogued more than one million SNPs, genome-wide, into a publicly accessible data-base (www.hapmap.org).
Approximately 11,500 of the SNPs recorded in Phase 1 are non-synonymous coding
SNPs. Other examples of genomic variation include gene deletions, inverted gene sequences, multiple copy gene duplications, segmental duplications and large-scale copy number variants. Each of these structural variants is shown schematically in Figure 1 .
In the year prior to the Hapmap publication, two landmark studies reported that large scale copy-number variations are distributed widely throughout the human genome, and that a high proportion of these encompass known genes 2, 3 . These studies were groundbreaking because they challenged the previously held view that the complete DNA sequences of any two individuals are 99.9% identical, the 0.1% difference being largely attributed to SNPs. Over the course of the following year, three further studies on CNVs followed 4, 5, 6 culminating in a current inventory of more than 600 structural variants within the normal human genome, comprising at least 100 million bases of DNA sequence (http://projects.tcag.ca/variation/). It is likely that this present index of CNVs is far from complete and new variants are continually being discovered 7 . In 2006, three studies specifically characterized deletion variants in the human genome 8, 9, 10 . Combined, these investigations described approximately 1000 deletions of varying size, with the majority being less than 10,000 base pairs.
McCarroll et al identified 10 genes which
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The CNV studies indicate that genes subject to structural variation appear to be significantly enriched in immune response, chemosensation and drug detoxification functions 3, 6, 9, 11 . Accordingly, it has been suggested that these genes may have roles in the adaptability and fitness of an organism in response to external pressures and that structural variation represents a process of adaptive evolution 7 . Indeed, selection on gene copy number has been reported for CCL3L1, an immune response gene, where relatively low copy number is associated with increased susceptibility to HIV/AIDS 12 . More recently, low FCGR3B copy number has been associated with increased susceptibility to immunologically mediated glomerulonephritis in patients with lupus 13 .
The implications of the studies outlined above for our understanding of human genetic diversity and for disease susceptibility are considerable. In addition, these studies are significant for the field of allogeneic hematopoietic stem cell transplantation (HSCT).
Non-synonymous coding SNPs and deletion polymorphisms hold importance as ways of generating potentially immunogenic transplantation antigens. SNPs in non-HLA genes can influence immune responses. Genes subject to CNV include MHC, KIR, and the genes encoding Fc and immunoglobulin receptors. Genes involved in drug detoxification which are prone to structural variation, and are of potential relevance in HSCT include those involved in the metabolism of busulfan (GST family), cyclophosphamide (cytochrome P450, GST family) and calcineurin inhibitors (cytochrome P450, UGT2B
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Minor Histocompatibility Antigens
Minor histocompatibility antigens (mHAs) were originally described by Snell in 1948 14 as non-MHC genetic loci sufficient to initiate allogeneic tissue rejection in congenic mouse strains (i.e. animals bred to be identical at the MHC locus but disparate at other areas of the genome). In 1978, Korngold et al demonstrated that lethal graft versus host disease (GVHD) could occur across minor histocompatibility barriers in mice and that GVHD appeared to be T cell mediated 15 . In a seminal paper in 1990, Wallny et al demonstrated that mHAs were peptides derived from normal cellular proteins presented by self MHC and that they were recognized by cytotoxic T lymphocytes (CTL) in a minor histoincompatible mouse strain 16 . In humans also, mHAs have been defined by allospecific CTL obtained from individuals primed in vivo through organ or bone marrow grafting and blood transfusions 17 (see Table 2 for current list of known human mHAs). GSTM1 and GSTT1 were also identified as homozygous null at appreciable frequency in the Hapmap population 8 . GSTT1 has been identified as a potential allo-antigen mediating It may also be possible to generate mHA specific CTL ex vivo from umbilical cord blood 50 . Another potential therapeutic strategy is to use mHA peptides to vaccinate either patients post HSCT or donors prior to transplantation 51 , in an attempt to augment the donor graft versus leukemia (GVL) response. The immunotherapeutic potential of tissuerestricted mHAs underlies the importance of identifying additional members of this group. In fact, in the last six months, three such mHA, each with immunotherapeutic potential in CML 52 , CLL 53 and myeloma 54 respectively have been discovered.
Immune Response Polymorphisms
While we know from syngeneic transplants that antigen disparity between host and donor is essential for the development of GVHD, the pathophysiology of the disease is complex. It is now generally accepted that the development of acute GVHD can be summarized into a three phase process 55 . In Phase I the conditioning regimen causes host tissue damage resulting in activation of inflammatory cytokines. In this inflammatory milieu there is increased expression of MHC and adhesion molecules leading to enhanced recognition of alloantigens by donor T cells, resulting in their activation and proliferation.
In the final phase, T cells induce further target tissue damage through cell-mediated cytotoxicity. In this model, inflammatory cytokines play a key role. It is now well established that many of the genes encoding cytokines are polymorphic and polymorphisms in these genes and in genes associated with innate immune response are amongst those most extensively studied in HSCT. It has been suggested that polymorphisms in these immune effector genes may be as important as the degree of HLA mismatch in determining GVHD severity and that typing for such allelic polymorphisms may, in the future, be an important consideration when selecting a HSCT donor 56 . The largest study (almost 1000 patient-donor pairs) was performed by Lin et al who found that the presence of a SNP in the promoter region of the recipient's IL-10 gene was significantly associated with a decreased risk of severe acute GVHD and death after HSCT 58 . A haplotype analysis showed that the IL-10 SNP in question was a specific marker for a particular IL-10 promoter haplotype. The authors hypothesized that the presence of this haplotype in the recipient caused increased IL-10 production and reduced GVHD-induced inflammation, although IL-10 levels were not measured in the study.
Cytokine Polymorphisms
This group has recently evaluated a non-synonymous coding SNP in the IL-10RB gene in the same cohort of patient-donor pairs 59 . On this occasion they found that the presence of this SNP in the donor was associated with a reduced incidence of severe acute GVHD, suggesting that genetic regulation of the IL-10 pathway plays a role in the development of acute GVHD. The functional significance of the IL-10RB SNP is currently unknown.
These two studies are amongst the best conducted in this area in that they evaluated a large sample population, they studied both donors and recipients, they investigated a homogenous population (HLA-identical siblings, T-cell replete transplants, identical GVH prophylaxis regimens), and at least in the first study, an attempt was made to validate results in an independent cohort (low frequency of the SNP of interest ultimately precluded this). Yet, they also serve as a striking illustration of the problems encountered within this area of research.
Perhaps the greatest weakness of these studies is the absence of a clear understanding of the biological significance of the findings. In their original study Lin et al showed that the presence of the IL-10 -592A/A genotype was a specific marker for a particular haplotype, which they proposed was associated with high IL-10 production. However earlier studies had suggested increased IL-10 production with the alternative IL-10 -592C/C genotype in autologous GVHD 60 . As mentioned previously IL-10 levels were not measured in the initial Lin study. Had they been checked and found to be high (as predicted), this finding would have been at odds with two earlier (albeit much smaller studies) showing an association between high IL-10 levels post HSCT and more severe acute GVHD 61 and increased mortality 62 .
Recently, high recipient IL-10 mRNA levels in peripheral blood mononuclear cells on day +14 post non-myeloablative HSCT were found to be associated with a reduced incidence of acute GVHD 63 . This finding is in keeping with an earlier study showing that high endogenous IL-10 production prior to myeloablative HSCT is protective against acute GVHD 64 . The cytokine-releasing profile of donor cells in response to recipient alloantigen stimulation has been shown to correlate with the development of acute GVHD, with a high frequency of donor cells producing IL-10 associated with the absence of acute GVHD after myeloablative HSCT 65 . In contrast to the studies noted previously 61, 62 , these studies suggest that higher levels of IL-10 in the peri-transplant period confer protection against the subsequent development of GVHD.
At the time of the Lin study it was suggested that IL-10 genotyping be included as part of the standard evaluation of a patient being considered for HSCT from an HLA-identical sibling donor 66 . Clearly, given the biological complexity of IL-10, we need a much better understanding of the functional significance of immune polymorphisms in this gene before this recommendation can be incorporated into clinical practice. As has been suggested by others, we also need a more extensive evaluation of as many genetic
polymorphisms as possible, in larger numbers of patients, so that the most informative variants, predictive of outcome are identified 67 .
Polymorphisms in Innate Immunity Genes
Although highly conserved across a wide range of species, innate immunity genes demonstrate substantial interindividual variability predominantly in the form of SNPs was identified as the first "susceptibility" gene for inflammatory bowel disease (IBD) 69, 70 .
There is clinical evidence that the innate immune system contributes to the development of acute GVHD through it's response to the translocation of bacterial toxins across the gastrointestinal mucosa 71 . Indeed, LPS antagonism has been shown to reduce GVHD severity in a mouse model In the setting of allogeneic HSCT the importance of KIR inhibitory receptors was first demonstrated in HLA haplotype mismatched transplants. In a subset of these patients, donor NK cell clones could not engage their class I inhibitory ligand as it was absent in the recipient, as a result of donor-recipient mismatch at the HLA class I group, resulting in the development of NK cell alloreactivity against host cells 82, 83 . Since NK cell alloreactivity appears to target primarily lymphohematopoietic cells a remarkable GVL effect was observed (at least in patients with AML) in these early studies, and it occurred 89 . They found that the presence of two activating KIRs, 2DS1 and 2DS2, in the donor was significantly associated with a decreased leukemic relapse rate, but this did not appear to be mediated through an HLA ligand interaction.
Overall, these studies suggest that genotyping for KIR to predict NK alloreactivity and optimize donor selection may be useful in the mismatched, unrelated and sibling transplant settings. Further investigation in this area is needed however as the results to date have not been uniformly consistent. Recently, Robien et al performed expanded genotyping of additional genes in the folate pathway and again found the MTHFR 677TT genotype to be associated with higher rates of mucositis, as was a deletion polymorphism in the thymidylate synthase (TS) gene 93 .
Polymorphisms of the glutathione S-transferase (GST) family of genes have also been investigated in the setting of HSCT. The major route of detoxification of busulfan is through conjugation with glutathione (GSH) which is catalyzed by the GST enzymes. A recent study of pediatric patients undergoing myeloablative HSCT for β -thalassemia found a significantly increased incidence of hepatic veno-occlusive disease (VOD) in patients with the GSTM1 null genotype compared with those with the GSTM1 positive genotype 94 . In this study, patients with the GSTM1 null genotype showed a significantly higher clearance and a lower steady-state concentration of busulfan after the first dose compared with those with a positive genotype. The authors proposed that this faster rate of busulfan metabolism depleted the GSH pool, allowing the busulfan metabolites generated to damage the sinusoidal endothelial cells and hepatocytes of the liver, culminating in the development of hepatic VOD.
Conclusions
As we delve deeper into the human genome, it is clear that the extent of normal variation therein is considerable. Genetic heterogeneity impacts on HSCT by generating hostdonor antigen disparity and by providing functional polymorphisms which may influence individual patient responses. Identifying additional clinically relevant transplant antigens is a priority because of the therapeutic possibilities and the potential for improved donor selection. Genotyping for KIR as a means to predict NK cell alloreactivity is also becoming increasingly relevant.
For
org From
Investigation of functional genetic polymorphisms is an area of expanding interest within the field. Other genes which have been evaluated in this regard and which were not included in this review include VDR 57 , ACE 95 , CPSI 95 and HFE 95 . The existing studies in this domain have a number of limitations, not least being that the biological significance of the genetic polymorphisms in these genes remains largely unknown. Almost all of these analyses have assessed a limited number of arbitrarily chosen SNPs in a single or limited number of genes. In this setting, the influence of SNPs in neighboring genes is unclear. Evaluation of candidate gene pathways using a linkage disequilibrium approach targeting SNPs in a particular haplotype is a more rational and recently applied method of investigation in this area 78 . Similarly unclear are the importance of SNPs determined to be of significance in individual studies, relative to that of SNPs identified in other studies.
In fact, many studies have demonstrated conflicting results. Also, many polymorphic genes known to play an important role in the immune response have never been evaluated in the context of HSCT (e.g. CTLA4 96 , FOXP3 97 ). The recent appreciation of the extent of undiscovered structural variation within the genome adds a further layer of complexity to the situation.
We now possess the ability to perform large scale SNP genotyping using high throughput technologies such as microarrays 98 , pyrosequencing 99 and liquid bead arrays 40 . Pretransplantation evaluation in the future is likely to comprise a more detailed genetic analysis of patient and donor with the ultimate goal of individualized patient treatment based on predictive risk scoring. Before this goal can be realized we need a more comprehensive examination of multiple genomic variants, undertaken in a prospective Mutis T, Blokland E, Kester M, Schrama E, Goulmy E. Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation. Blood. 2002;100:547-552. 2DP1 2DL1 3DP1  2DL2 2DL5B 2DS3  2DL3 2DS2  3DL2  2DS1  2DS5  2DS4  2DL5A   3DL1   3DS1   2DL4   3DL3  2DP1 2DL1 3DP1  2DL3  3DL2  2DS4  3DL1  2DL4   3DL3  3DP1  2DL2  2DS2  3DL2  3DL1  2DL4   3DL3  2DP1 2DL1 3DP1  2DL2  3DL2  2DS1  2DS5  2DL5A  3DS1  2DL4   3DL3  2DL1  3DL2  2DL4  2DL3  2DL4  2DL4 3DL1  2DS4   3DL3  2DP1 2DL1 3DP1  2DL2  3DL2  2DL4  2DL3  3DL1  2DS4 For personal use only. on October 28, 2017. by guest www.bloodjournal.org From
